David M. Selim
Analyst
Piper Sandler
Equibles does not estimate personal net worth.
About David M. Selim
David M. Selim is recorded as Analyst at Piper Sandler. David M. Selim has spoken on 3 earnings calls and 1 other investor event across 4 companies, most recently for Jazz Pharmaceuticals plc on November 2, 2026. Those appearances were for Jazz Pharmaceuticals plc (JAZZ), Harmony Biosciences Holdings, Inc. (HRMY), Supernus Pharmaceuticals, Inc. and Definium Therapeutics, Inc. (DFTX). The companies whose calls David M. Selim spoke on are classified in the Healthcare sector.
David M. Selim on recent calls
“Just wanted to get your thoughts on the trajectory of the product longer term, given the presentation of Amgen's Indelta survival data and first-line extensive stage small cell lung.”
“So I wanted to drill down more on Greg's question on different indications. So we already have a glimpse of potential other indications. There's alchemies with an ADHD program and also fatigue, an MS and Parkinson's program.”
“Jack, I wanted to come back to your comments on more business development and flexibility. So you have a history of doing primarily commercial stage transactions.”
“One, in terms of the patient experience, in terms of patient monitoring, how confident are you that in practice only one dosing session monitor will be needed to monitor the patient?”
Affiliation history
-
Piper Sandler
Analyst
Transcript header (unverified)
Current
Company network
Supernus Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare
Recent activity
-
-
-
Conference
Joint Supernus and Indivior Conference Call and Webcast
Supernus Pharmaceuticals, Inc.
-